Lexicon Pharma (LXRX) Tops Q3 EPS by 14c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.19 +1.86%
EPS Growth %: -600.0%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -600.0%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.35), $0.14 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $27.7 million versus the consensus estimate of $9.68 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
